Moataz Razeen is a postdoctoral research fellow at Byers Eye Institute at Stanford. He has been working in cutting edge retinal imaging research since 2013. He specializes in running research studies using adaptive optics scanning light ophthalmoscopy (AOSLO) mainly to characterize disease entities and study microscopic changes that occur with treatment and/or as part of disease progression. Dr. Razeen graduated from Alexandria Faculty of Medicine, Egypt in early 2013 to rapidly join New York Eye and Ear Infirmary’s research team months later under the supervision of Drs. Richard Rosen and Toco Chui. In 2014, he was then recruited by the inventors of the technology; Drs. Alfredo Dubra and Joe Carroll, at the Medical College of Wisconsin as the Ocular Imaging Fellow of their Advanced Ocular Imaging Program. In late 2016, he joined Dr. Dubra in his transition to Stanford University. Dr. Razeen has been involved in multiple projects since he started doing retinal research. At New York Eye and Ear Infirmary, he used the AOSLO technology combined with oral fluorescein to characterize normal retinal microvasculature density in normal subjects and used the data to compare to patients with vascular retinal conditions including diabetic retinopathy and retinal vein occlusion. At the Medical College of Wisconsin, he shifted gears to study photoreceptor abnormalities in patients with inherited retinal degenerations including Stargardt disease, retinitis pigmentosa and Achromatopsia. Dr. Razeen has been an active member of the Association for Research in Vision and Ophthalmology (ARVO) presenting in yearly meetings. His work has been published in a wide array of peer reviewed journals including IOVS, TVST, Retina and OPO. He is currently working on utilizing the technology to discover an early biomarker of glaucoma. At present, Dr. Razeen resides in Silicon Valley, California.
Retinal imaging including optical coherence tomography, adaptive optics scanning light ophthalmoscopy, microperimetry or multimodal imaging of inherited retinal degenerations and vascular retinal conditions.